QuidelOrtho Q2 revenue falls to $614 million; GAAP net loss widens to $255 million
QuidelOrtho reported second-quarter 2025 revenue of $614 million, down from $637 million a year earlier, and a GAAP net loss of $255 million, or $3.77 per diluted share, versus a $148 million loss in the prior-year quarter. The loss includes $179 million in mostly non-cash restructuring, integration and other charges, while adjusted diluted EPS rose to $0.12 from a loss of $0.07 and adjusted EBITDA rose to $107 million from $90 million. The company reiterated its full-year 2025 guidance.
Key points
- Total revenue was $614 million versus $637 million, down about 4%, mainly due to lower COVID-19 and Donor Screening revenue.
- GAAP diluted loss per share was $3.77 versus $2.20 a year earlier; GAAP net loss was $255 million.
- Adjusted diluted EPS was $0.12 versus a loss of $0.07; adjusted EBITDA margin was 17%, a 330 basis point improvement.
- Full-year 2025 guidance was reiterated, including total revenue of $2.60 to $2.81 billion and adjusted diluted EPS of $2.07 to $2.57.
The filing
Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.